These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 36042198)

  • 21. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.
    Madelain V; Guedj J; Mentré F; Nguyen TH; Jacquot F; Oestereich L; Kadota T; Yamada K; Taburet AM; de Lamballerie X; Raoul H
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27736754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.
    Chiba S; Kiso M; Nakajima N; Iida S; Maemura T; Kuroda M; Sato Y; Ito M; Okuda M; Yamada S; Iwatsuki-Horimoto K; Watanabe T; Imai M; Armbrust T; Baric RS; Halfmann PJ; Suzuki T; Kawaoka Y
    mBio; 2021 Feb; 13(1):e0304421. PubMed ID: 35100870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.
    Pires de Mello CP; Tao X; Kim TH; Bulitta JB; Rodriquez JL; Pomeroy JJ; Brown AN
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of favipiravir in the treatment of COVID-19.
    Joshi S; Parkar J; Ansari A; Vora A; Talwar D; Tiwaskar M; Patil S; Barkate H
    Int J Infect Dis; 2021 Jan; 102():501-508. PubMed ID: 33130203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19.
    Iwata S; Kobayashi O; Kurashima K; Doi Y; Kunishima H; Shinkai M; Tsushima K; Yamato M; Kano A; Hibino M; Yamatake T; Sakurai T; Ogura T
    J Infect Chemother; 2024 Mar; 30(3):219-227. PubMed ID: 37832822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Favipiravir in the Battle with Respiratory Viruses.
    Smyk JM; Majewska A
    Mini Rev Med Chem; 2022; 22(17):2224-2236. PubMed ID: 35184710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment:
    Yildiz Pekoz A; Akbal Dagistan O; Fael H; Culha M; Erturk A; Basarir NS; Sahin G; Serhatli M; Cakirca G; Tekin S; Sen LS; Sevim M; Mulazimoglu Durmusoglu L; Yegen BC
    Drug Deliv; 2022 Dec; 29(1):2846-2854. PubMed ID: 36062490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.
    Pohl MO; Martin-Sancho L; Ratnayake R; White KM; Riva L; Chen QY; Lieber G; Busnadiego I; Yin X; Lin S; Pu Y; Pache L; Rosales R; Déjosez M; Qin Y; De Jesus PD; Beall A; Yoh S; Hale BG; Zwaka TP; Matsunaga N; García-Sastre A; Stertz S; Chanda SK; Luesch H
    ACS Infect Dis; 2022 Jul; 8(7):1265-1279. PubMed ID: 35766385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.
    Lingas G; Rosenke K; Safronetz D; Guedj J
    PLoS Comput Biol; 2021 Jan; 17(1):e1008535. PubMed ID: 33411731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
    Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
    Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
    Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.
    Aktaş A; Tüzün B; Aslan R; Sayin K; Ataseven H
    J Biomol Struct Dyn; 2021 Nov; 39(18):7263-7273. PubMed ID: 32783586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
    Kundu S; Sarkar D
    Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent Inactivation of Human Respiratory Viruses Including SARS-CoV-2 by a Photoactivated Self-Cleaning Regenerative Antiviral Coating.
    Kumar U; Fox CR; Kolanthai E; Neal CJ; Kedarinath K; Fu Y; Marcelo E; Babu B; Parks GD; Seal S
    ACS Appl Mater Interfaces; 2022 Sep; 14(36):40659-40673. PubMed ID: 36004755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
    Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T
    Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
    Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.
    Erdem HA; Korkma PE; Çağlayan D; Işıkgöz Taşbakan M; Yamazhan T; Taşbakan MS; Sayıner A; Gökengin D
    Turk J Med Sci; 2021 Jun; 51(3):912-920. PubMed ID: 33237663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.